Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,457 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
5.8
Industry P/E
--
EV/EBITDA
-71.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$5.6
EPS
$-3.2
Face value
--
Shares outstanding
115,554,295
CFO
$-270.79 Mln
EBITDA
$-346.12 Mln
Net Profit
$-375.21 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
| -1.1 | 2.8 | -1.1 | 45.5 | 27.9 | 40.8 | 37.3 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
| -12.6 | 114.9 | 98.0 | 104.3 | -18.3 | -29.8 | 4.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Viking Therapeutics (VKTX)
|
34.8 | 3,457.4 | 0.0 | -359.6 | -- | -47.3 | -- | 5.8 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 7.3 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective... agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. Address: 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121 Read more
President, CEO & Director
Dr. Brian Lian Ph.D.
President, CEO & Director
Dr. Brian Lian Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Viking Therapeutics Inc (VKTX) is $34.80 (NASDAQ) as of 02-Apr-2026 16:18 EDT. Viking Therapeutics Inc (VKTX) has given a return of 27.86% in the last 3 years.
Since, TTM earnings of Viking Therapeutics Inc (VKTX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-11.15
|
6.28
|
|
2024
|
-40.75
|
5.09
|
|
2023
|
-21.69
|
5.35
|
|
2022
|
-10.45
|
4.95
|
|
2021
|
-6.43
|
1.75
|
The 52-week high and low of Viking Therapeutics Inc (VKTX) are Rs 43.15 and Rs 18.92 as of 03-Apr-2026.
Viking Therapeutics Inc (VKTX) has a market capitalisation of $ 3,457 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Viking Therapeutics Inc (VKTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$1.84
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.